Cardiff Oncology
CRDF
94 hedge funds and large institutions have $141M invested in Cardiff Oncology in 2021 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 30 increasing their positions, 26 reducing their positions, and 15 closing their positions.
27% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 15
15% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 26
12% more call options, than puts
Call options by funds: $2.88M | Put options by funds: $2.58M
4% more funds holding
Funds holding: 90 → 94 (+4)
17.24% less ownership
Funds ownership: 70.64% → 53.41% (-17%)
20% less capital invested
Capital invested by funds: $176M → $141M (-$35.7M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$2.4M |
| 2 |
Goldman Sachs
New York
|
+$1.73M |
| 3 |
William Blair & Company
Chicago,
Illinois
|
+$1.32M |
| 4 |
CC
Caxton Corporation
Princeton,
New Jersey
|
+$1.12M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$12M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$9.28M |
| 3 |
CA
Corriente Advisors
Fort Worth,
Texas
|
-$9.2M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$4.11M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$3.08M |
CRDF Hedge Fund Activity: Q3 2021 in Review
94 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q3 2021, worth a combined $141M — down 20% from $176M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new CRDF positions and 15 closed out — a net gain of 4 holders — while 30 added to existing stakes and 26 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $2.4M. The largest seller was Eventide Asset Management, cutting an estimated $12M.
- 94 institutional investors held Cardiff Oncology (CRDF) as of Q3 2021, up from 90 in Q2 2021.
- Funds reported $141M of Cardiff Oncology stock for Q3 2021, down 20% quarter-over-quarter.
- 19 funds opened new Cardiff Oncology positions in Q3 2021 and 15 closed out, a net change of +4 holders.
- The largest Cardiff Oncology buyer in Q3 2021 was Janus Henderson Group, an estimated $2.4M added.
- The largest Cardiff Oncology seller in Q3 2021 was Eventide Asset Management, an estimated $12M sold.
Based on aggregated 13F filings for Q3 2021.